T

Tasman Health Care | Oncology Research

Research site
(Unclaimed)
Location
Suite 1 Level 3 123 Nerang St, Southport, Queensland, Australia
Site insights

Top conditions

Prostatic Cancer (2 trials)

Giant Cell Arteritis (1 trial)

Polymyalgia Rheumatica (1 trial)

Urinary Bladder Cancer (1 trial)

Neoplasm Metastasis (1 trial)

Top treatments

Darolutamide
Pembrolizumab
Xofigo
Androgen
Radium-223 Dichloride
ABBV-154

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

3 of 5
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcin...

Active, not recruiting
HNSCC
NSCLC
Drug: Eftilagimod alpha
Drug: Pembrolizumab

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Enrolling
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: NAH therapy
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Trial sponsors

Bayer logo

Bayer (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems